Skip to main content

Advertisement

SpringerLink
Log in

ASO Author Reflections: HIPEC Immunogenic Changes Could be Further Exploited by Immunotherapy to Treat Peritoneal Metastases from Colorectal Cancer

  • ASO Author Reflections
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Quenet F, Elias D, Roca L, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(2):256–66.

    Article  CAS  PubMed  Google Scholar 

  2. Zunino B, Rubio-Patino C, Villa E, et al. Hyperthermic intraperitoneal chemotherapy leads to an anticancer immune response via exposure of cell surface heat shock protein 90. Oncogene. 2016;35(2):261–8.

    Article  CAS  PubMed  Google Scholar 

  3. Geva R, Alon G, Nathanson M, et al. PD-1 blockade combined with heated intraperitoneal chemotherapy improves outcome in experimental peritoneal metastases from colonic origin in a murine model. Ann Surg Oncol. 2023. https://doi.org/10.1245/s10434-022-13025-7.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Peritoneal Surface Malignancy and Melanoma Unit, Department of Surgery A, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel

    Gilad Alon MD, Guy Lahat MD & Eran Nizri MD, PhD

  2. Laboratory of Surgical Oncology, Division of Surgery, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel

    Gilad Alon MD, Guy Lahat MD & Eran Nizri MD, PhD

  3. Institute of Oncology, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel

    Ravit Geva MD

  4. Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel

    Ravit Geva MD, Guy Lahat MD & Eran Nizri MD, PhD

Authors
  1. Gilad Alon MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ravit Geva MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Guy Lahat MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Eran Nizri MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eran Nizri MD, PhD.

Ethics declarations

Disclosures

Ravit Geva: honoraria (self) from Roche, MSD, Merck, Medison, Janssen, Pfizer, and BMS. Advisory/consultancy in AstraZeneca (7/2022), BOL Pharma (ended 3/2022), Roche, Ranium, JNJ, Bayer, and MSD (6/2022). Leadership roles in Pyxis, and medical lead. Shareholder/stockholder/stock options in Pyxis (options). Travel/accommodations/expenses: Takeda (1/2022) and Medison (6/2022).

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Alon, G., Geva, R., Lahat, G. et al. ASO Author Reflections: HIPEC Immunogenic Changes Could be Further Exploited by Immunotherapy to Treat Peritoneal Metastases from Colorectal Cancer. Ann Surg Oncol 30, 2664–2665 (2023). https://doi.org/10.1245/s10434-023-13254-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-023-13254-4

Search

Navigation